vTv Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:VTVT   3:59:44 PM EDT
2.31
-0.09 (-3.75%)
Products, Strategic Combinations

vTv Therapeutics Announces Licensing Agreement For Novel Nrf2 Activator To Anteris Bio

Published: 12/15/2020 12:43 GMT
vTv Therapeutics Inc - Ordinary Shares - Class A (VTVT) - Vtv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio.
Vtv Therapeutics Inc - Anteris Will Pay Vtv an Upfront Payment of $2 Million.
Vtv Therapeutics Inc - Vtv May Be Eligible for Up to $151 Million of Future Development, Regulatory and Commercial Sales Milestones.
Vtv Therapeutics Inc - Vtv Will Receive a Minority Equity Interest in Anteris Bio.